Stay updated on Phase II Pembrolizumab Plus GVD Clinical Trial
Sign up to get notified when there's something new on the Phase II Pembrolizumab Plus GVD Clinical Trial page.

Latest updates to the Phase II Pembrolizumab Plus GVD Clinical Trial page
- Check3 days agoChange DetectedThe page now displays a 403 Forbidden error with a basic header and footer. It shows no study details or locations, indicating the page is currently inaccessible.SummaryDifference23%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe page's revision marker was bumped from v3.6.5 to v3.6.6, indicating a maintenance/metadata update rather than a substantive change to the study details.SummaryDifference0.0%

- Check45 days agoChange DetectedThe page’s revision history now includes a new entry for v3.6.5 dated 2026-08-07, along with prior August revisions; this indicates an update to the page’s revision history and timestamps.SummaryDifference0.2%

- Check60 days agoChange DetectedRevision label updated from v3.6.3 to v3.6.4, signaling a routine deployment or patch. No study details or user-facing content appears to be altered.SummaryDifference0.0%

- Check67 days agoChange DetectedISRT sections were added (PART 3A/3B) with reference to ISRT guidelines for nodal disease. Eligibility criteria were updated to specify PET-based Lugano measurable disease and autoimmune disease exclusions, and the study endpoints include a 5-year disease-free survival assessment.SummaryDifference1%

- Check81 days agoChange DetectedThe page metadata was updated to reflect a new revision (v3.6.3) and more recent update dates (2026-06-26 and 2026-06-29), indicating an administrative update to the study record.SummaryDifference0.2%

Stay in the know with updates to Phase II Pembrolizumab Plus GVD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase II Pembrolizumab Plus GVD Clinical Trial page.